Влияние селективного активатора рецептора витамина D парикальцитола на сердечно-сосудистую систему и кардиоренальную протекцию
Аннотация
Широкое распределение рецепторов витамина D в организме человека обусловливает плейотропные эффекты активации рецепторов витамина D. В свете новых исследований мы обсуждаем вероятные положительные эффекты селективного активатора рецепторов витамина D, парикальцитола, на сердечно-сосудистую систему у пациентов с хронической сердечной недостаточностью и у пациентов с хронической болезнью почек. Парикальцитол вероятно мог бы привнести дополнительные клинические преимущества по сравнению со стандартным лечением хронической почечной и сердечной недостаточности, особенно при наличии кардиоренального синдрома.
Об авторах
Д. . Дупланчич
Университет Сплита, Хорватия
Россия
Россия
М. . Цезарич
Окружной госпиталь По-жега, Хорватия
Россия
Россия
Н. К. Поляк
Университет Сплита, Хорватия
Россия
Россия
М. . Радман
Университет Сплита, Хорватия
Россия
Россия
В. . Ковачич
Университет Сплита, Хорватия
Россия
Россия
Ж. . Радич
Университет Сплита, Хорватия
Россия
Россия
В. . Рогозич
Университет Сплита, Хорватия
Россия
Россия
Список литературы
1. Webb RA. Who, what, where and when - influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 2006;92:17-25
2. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:8-28
3. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: A review. Altern Med Rev 2005;10:94-111
4. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591
5. Gouni-Berthold I, Krone W, Berthold HK. Vitamin D and cardiovascular disease. Curr Vasc Pharmacol 2009;7:414-422
6. Parker J, Hashmi O, Dutton D, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010;65:225-236
7. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007;20:713-719
8. Freedman BI, Wagenknecht LE, Hairston KG, et al. Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J Clin Endocrinol Metab 2010;95:1076-1083
9. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(Suppl 6):S1689-S1696
10. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991;87:1889-1895
11. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 2008;11:7-12
12. Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998;54:1463-1469
13. Bellows CG, Reimers SM, Heersche JN. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res 1999;297:249-259
14. Drissi H, Pouliot A, Koolloos C, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002;274:323-333
15. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004;279:35798-35802
16. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007;103:521-524
17. Meems LM, van der Harst P, van Gilst WH, de Boer RA. Vitamin D biology in heart failure: molecular mechanisms and systematic review. Curr Drug Targets 2011;12:29-41
18. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008;294:1059-1064
19. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846-854
20. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009; 89:1321-1327
21. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:1931-1942
22. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167(16):1730-1737
23. Dobnig H, Pilz S, Scharnagl H, Renner W, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihy-droxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340-1349
24. Inaguma D, Nagaya H, Hara K, et al. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with predialysis chronic kidney disease. Clin Exp Nephrol 2008;12:126-131
25. Baker LR, Abrams L, Roe CJ, et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35:661-669
26. Moe SM, Drüeke TB, Block GA, et al. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-S130
27. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-1953
28. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997;96:1755-1760
29. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125
30. Bianchi ML, Colantonio G, Campanini F, et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994;9:1595-1599
31. Yildiz A, Memisoglu E, Oflaz H, et al. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant 2005;20:760-767
32. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003;9 Suppl 4: S305-S309
33. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119
34. [No authors listed]. VI. Causes of death in ESRD. Am J Kidney Dis 1999;34(2 Suppl 1):S87-S94
35. [No authors listed]. V. Patient mortality and survival in ESRD. Am J Kidney Dis 1999;34:(2 Suppl 1):S74-S86
36. Goodman WG, Coburn JW. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 1992;43:227-237
37. Demer LL, Tintut Y Vascular calcification: pathobiology of multifaceted disease. Circulation 2008;117:2938-2948
38. Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 2006;21:484-490
39. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007;18:2116-2124
40. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-436
41. Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. J Am Soc Nephrol 2000;11:2088-2094
42. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Vitamin D and vascular calcification in chronic kidney disease. Bone 2009; 45 Suppl 1:S26-S29
43. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007;67:1999-2012
44. Cheng J, Zhang W, Zhang X, Li X, Chen J. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a metaanalysis. Clin J Am Soc Nephrol 2012;7:391-400
45. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490
46. Brown JA, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002;139:279-284
47. Nakane M, Ma J, Rose AE, et al. Differential effects of vitamin D analogs on calcium transport. J Steroid Biochem Mol Biol 2007;103:84-89
48. Sprague SM, Lerma E, McCormmick D, et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;38:S51-S56
49. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997;30:105-112
50. Rodriguez M, Martinez-Moreno JM, Rodríguez-Ortiz ME, Mufioz-Castafieda JR, Almaden Y Vitamin D and vascular calcification in chronic kidney disease. Kidney Blood Press Res 2011;34:261-268
51. Li X, Speer MY, Yang H, Bergen J, Giachelli CM. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol 2010;30: 321-326
52. Sanchez-Nifio MD, Bozic M, Córdoba-Lanús E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012;302:647-657
53. Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 1986;105:649-654
54. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394-1402
55. Park JW, Bae EH, Kim IJ, et al. Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol 2010;298:301-313
56. Sochorová K, Budinský V, Rozková D, et al. Paricalcitol (19-nor-1, 25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol. 2009;133:69-77
57. Ari E, Kedrah AE, Alahdab Y, et al. Antioxidant and reno-protective effects of paricalcitol on experimental contrast-induced nephropathy model. Br J Radiol 2012;85:1038-1043
58. Meems LM, Cannon MV, Mahmud H, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol 2012;132:282-289
59. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 2009;29:465-472
60. Park JW, Cho JW, Joo SY et al. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. Eur J Pharmacol 2012;683:301-309
61. Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-1806
62. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 2010;32:296-304
63. Kong J, Kim GH, Wei M, et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010;177:622-631
64. Mizobuchi M, Nakamura H, Tokumoto M, et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010;121: 188-192
65. Fraga C, Blanco M, Vigo E, et al. Autogenesis of the vitamin D receptor in the rat heart. Histochem Cell Biol 2002;117:547-550
66. Wu-Wong JR, Noonan W, Nakane M, et al. Vitamin d receptor activa-tion mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. Int J Endocrinol Epub February 10, 2010
67. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709-715
68. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-866
69. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. Engl J Med 31, 2003;349:446-456
70. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemo-dialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-1865
71. Cozzolino M, Brancaccio D, Cannella G, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH < = 150 pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant 2012;27(9):3588-3594
72. He W, Kang YS, Dai C, Liu Y Blockade of Wnt/? - catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011;22:90-103
73. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The role of paricalcitol on proteinuria. J Ren Care 2011;37:80-84
74. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68:2823-2828
75. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-1551
76. Thadhani R, Appelbaum E, Pritchett Y. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-684 Статья переведена на русский язык и публикуется из журнала Clinical Interventions in Aging 2013:8 149156 doi: 10.2147/CIA.S38349 с разрешения авторов и согласно условиям лицензионного соглашения «Creative Commons attribution-noncommerical license».
Рецензия
Для цитирования:
Дупланчич Д., Цезарич М., Поляк Н.К., Радман М., Ковачич В., Радич Ж., Рогозич В. Влияние селективного активатора рецептора витамина D парикальцитола на сердечно-сосудистую систему и кардиоренальную протекцию. Нефрология. 2014;18(2):25-32.
For citation:
Duplancic D., Cesarik M., Poljak N.K., Radman M., Kovacic V., Radic J., Rogosic V. The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. Nephrology (Saint-Petersburg). 2014;18(2):25-32. (In Russ.)
Просмотров:
375
Послать статью по эл. почте 